Search Results
Your search for multiple myeloma matches 1442 pages
Showing 351 - 400Model May Help Identify Subtypes of Multiple Myeloma
Researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for subtypes of multiple myeloma. They also identified potential targeted treatments based on the findings, which were reported by...
Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the evolving treatment paradigm for patients with newly diagnosed multiple myeloma in which clinical trials are suggesting the addition of a fourth drug to induction treatment regimens and new drug classes are improving treatment for...
Numerous Regimens Proposed for Relapsed or Refractory Myeloma
Although patients with multiple myeloma can respond to initial treatment, once a patient has had three or four different types of therapy, and the disease is deemed relapsed or refractory, treatment becomes more complicated. This is related to both clinical characteristics, as patients may develop...
NCCN 2021 Virtual Congress on Hematologic Malignancies: Round-up
The National Comprehensive Cancer Network’s 2021 Virtual Congress on Hematologic Malignancies took place from October 14 to October 16. The meeting focused on updates to the NCCN Clinical Practice Guidelines in Oncology; new, emerging, and novel therapeutic agents; advances in cancer care; and the...
Showcasing 50 Years of Advances in Cancer Research and Treatment
The AACR Cancer Progress Report 2021, published on October 13, celebrates the gains made in cancer research since President Richard Nixon signed the National Cancer Act into law on December 23, 1971, especially against such life-threatening cancers as metastatic melanoma and lung cancer.1 The...
Study Examines Breakthrough COVID-19 Infection in Vaccinated Patients With Hematologic Cancers
People with blood cancers are at a higher risk than healthy individuals for severe infection with COVID-19; furthermore, research suggests that they do not always achieve optimal protection from vaccination. A new study published by Pagano et al in the journal Blood—the first to report on...
Patients With Multiple Myeloma May Lack T-Cell Responses to COVID-19 Vaccination
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccine may also fail to mount a T-cell response, according to research from the Icahn School of Medicine at Mount Sinai. Concerningly, this scenario was most common among patients actively treated with anti-CD38 and...
Melphalan Flufenamide Withdrawn From the U.S. Market
On October 22, Oncopeptides announced its decision to withdraw melphalan flufenamide (Pepaxto), a first-in-class peptide-drug conjugate, from the market in the United States, following results from the phase III OCEAN study in patients with relapsed or refractory multiple myeloma. The decision to...
Overall Survival in the MAIA Trial: Daratumumab, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
As reported in The Lancet Oncology by Thierry Facon, MD, and colleagues, an interim analysis of overall survival in the pivotal phase III MAIA trial has shown a significant benefit with the addition of daratumumab to lenalidomide/dexamethasone in newly diagnosed, transplant-ineligible patients with ...
AACR Cancer Progress Report 2021 Showcases 50 Years of Advances in Cancer Research and Treatment
The AACR Cancer Progress Report 2021 celebrates the gains made in cancer research since the National Cancer Act was signed into law on December 23, 1971. The report also recognizes the negative impact the COVID-19 pandemic has had on cancer research and patient care, the disproportionate toll both...
Study Finds Some Pancreatic Cancer Trial Eligibility Criteria Disproportionately Exclude Black Patients
Although lack of clinical trial participation is associated with worse survival outcomes in some malignancies, data show that Black patients with cancer represent just 7.3% of participants—and only 4.5% for such cancers as multiple myeloma—in cancer clinical trials, compared with 84.2% for White...
Triplet Therapy and Lenalidomide Maintenance to Prevent Disease Progression in High-Risk Smoldering Myeloma
In a single-center phase II trial reported in JAMA Oncology, Kazandjian et al found that triplet therapy with carfilzomib, lenalidomide, and dexamethasone (KRd), followed by lenalidomide maintenance, produced high rates of measurable residual disease (MRD)-negative complete response and freedom...
CASSIOPEIA Part 2: Maintenance Daratumumab After Initial Therapy for Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has shown significantly prolonged progression-free survival with maintenance daratumumab vs observation following induction and consolidation with or without...
Paradox Between Cost and Hematopoietic Cell Transplant Rate in Latin America
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Gregorio Jaimovich, MD, Director of the Bone Marrow Transplant Program at Favaloro University Hospital in Buenos Aires. Distinguished expert on radiation therapy and bone...
Saad Z. Usmani, MBA, MD, on Multiple Myeloma: Updated Results From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel
Saad Z. Usmani, MBA, MD, of the Levine Cancer Institute, discusses new data on the CAR T-cell therapy ciltacabtagene autoleucel, a single infusion of which yielded early, deep, and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma (Oral Abstract MM-119).
Expert Point of View: Gordon Cook, MBChB, PhD and Sagar Lonial, MD
The OPTIMUM/MUKnine1 and FORTE2 updates were discussed at the 2021 ASCO Annual Meeting by Gordon Cook, MBChB, PhD, Clinical Director of the National Institute for Health Research In Vitro Diagnostics Cooperative and the Clinical Trials Unit in Hematology of the University of Leeds, United Kingdom....
Myeloma Trial Updates: Focus on High-Risk Patients and Measurable Residual Disease Negativity
Newly diagnosed patients with multiple myeloma deemed at high risk for disease progression may achieve sustained measurable residual disease (MRD) negativity with newer regimens and transplantation, and this may translate into longer progression-free survival. That’s the key take-away message from...
ASCO 2021: Roundup of Studies You May Have Missed
As ASCO Annual Meeting attendees know by now, clinicians don’t have to be at McCormick Place to hear practice-changing findings and forward-looking advances in the field of oncology. Interesting content was no exception at the 2021 conference, so in addition to covering the biggest news from the...
Bispecific Antibodies Find a Place in B-Cell Lymphoma Treatment
In relapsed or refractory B-cell lymphomas, bispecific T-cell engager antibodies are finding a place in the treatment algorithm, said Christopher Flowers, MD, MS, FASCO, Professor and Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston. At the...
Consolidation Treatment With VRD Followed by Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma
In a phase III European Myeloma Network trial (EMN02/HOVON95) reported in the Journal of Clinical Oncology, Sonneveld et al found that consolidation with bortezomib, lenalidomide, and dexamethasone (VRD) vs no consolidation followed by maintenance lenalidomide was associated with significantly...
Roundup of Notable Abstracts in Hematologic Malignancies
In addition to covering the biggest news from the meeting in other articles, The ASCO Post brings you these brief news summaries of notable abstracts in multiple myeloma, lymphoma, and leukemia. Maintenance Daratumumab in Multiple Myeloma Part 2 of the CASSIOPEIA trial in 866 patients with newly...
Expert Point of View: Surbhi Sidana, MD
The session’s invited discussant Surbhi Sidana, MD, Assistant Professor of Medicine, Stanford University, said chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies targeting myeloma are emerging as potentially effective options for patients with highly refractory disease. For...
Bispecific Antibodies Advance in Relapsed or Refractory Multiple Myeloma
For the challenging population of patients with multiple myeloma who have become refractory to essentially all current treatments, new approaches are much needed. Early clinical trials data suggest bispecific antibodies may help meet this need, as suggested by studies presented at the 2021 ASCO...
Treatment of Relapsed Myeloma: Options Include New Drugs, Novel Combinations
The treatment paradigm for multiple myeloma continues to evolve at a rapid pace with the introduction of new drugs and the development of drug combinations, particularly the initial approach to the treatment of newly diagnosed multiple myeloma.1 One major shift in the treatment of newly diagnosed...
Subcutaneous Daratumumab Added to Pomalidomide Plus Dexamethasone Improves Progression-Free Survival in Multiple Myeloma
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous (SC) daratumumab to oral...
Daratumumab and Hyaluronidase-fihj With Pomalidomide Plus Dexamethasone in Multiple Myeloma
On July 9, 2021, daratumumab and hyaluronidase-fihj was approved for use in combination with pomalidomide and dexamethasone (Pd) for treatment of adults with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.1 Supporting...
Pembrolizumab Combined With Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
On May 5, 2021, pembrolizumab was granted accelerated approval for use in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal...
Addition of Venetoclax to Daratumumab/Dexamethasone With or Without Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
In a phase I study reported in the Journal of Clinical Oncology, Bahlis et al found that venetoclax plus daratumumab/dexamethasone (VenDd) and VenDd with bortezomib (VenDVd) produced high rates of durable responses in patients with relapsed or refractory multiple myeloma with t(11;14) translocation ...
Muhamed Baljevic, MD, on Multiple Myeloma: Review of Novel Management Strategies
Muhamed Baljevic, MD, of the University of Nebraska Medical Center, reviews the outlook for treating patients with relapsed and refractory multiple myeloma, the rapidly expanding array of therapeutic options with novel mechanisms of action, and the challenges of sequencing treatments.
Muhamed Baljevic, MD, on Multiple Myeloma: Review of Novel Management Strategies
Muhamed Baljevic, MD, of the University of Nebraska Medical Center, reviews the outlook for treating patients with relapsed and refractory multiple myeloma, the rapidly expanding array of therapeutic options with novel mechanisms of action, and the challenges of sequencing treatments.
Isatuximab-irfc in Relapsed or Refractory Multiple Myeloma
On March 31, 2021, the anti-CD38 monoclonal antibody isatuximab-irfc was approved for use in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.1 Supporting Efficacy Data...
Historic, Present, and Future Perspectives on Breast Cancer in Egypt
Breast cancer is the most frequently diagnosed cancer among women around the world, making it a significant public health problem.1 The disease affects both men and women, although it is rare in men, accounting for just 1% of all breast cancer diagnoses in the United States and less than 0.1% of...
Nina Shah, MD, on Newly Diagnosed Multiple Myeloma: Novel Combination Therapies
Nina Shah, MD, of the University of California, San Francisco, discusses triplet drug combinations that are the current standard of care for transplant-eligible and -ineligible patients with multiple myeloma, as well as quadruplet therapies that demonstrate depth of response in newly diagnosed...
Teclistamab Shows Efficacy, Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
In a phase I trial (MajesTEC-1) reported in The Lancet, Saad Z. Usmani, MD, FACP, and colleagues found that the B-cell maturation antigen (BCMA)-CD3 bispecific antibody teclistamab produced a high rate of durable responses at the recommended phase II dose in patients with relapsed or refractory...
S. Vincent Rajkumar, MD, on Multiple Myeloma: Defining Cure
S. Vincent Rajkumar, MD, of the Mayo Clinic, talks about how, in light of the fact that multiple myeloma has been turned into a chronic disease for many people, what it means to “cure” patients; the difference between curable and cured in multiple myeloma; and key studies he is involved in that...
Do Muscle-Strengthening Activities Plus Aerobic Activities Reduce Cancer Mortality?
Regular muscle-strengthening exercises associated with aerobic activities can reduce cancer mortality, according to a systematic review of epidemiologic studies published by Nascimento et al in the International Journal of Behavioral Nutrition and Physical Activity. Workouts with activities like...
Study Finds COVID-19 Vaccine Is Safe in Patients With Hematologic Malignancies, but 25% of These Patients Do Not Produce Detectable Antibodies
About one in four patients with blood cancer fail to produce detectable antibodies after COVID-19 vaccination, but results vary substantially by type of blood cancer, according to a study by Greenberger et al published in the journal Cancer Cell. Although earlier studies have shown that certain...
Defining Cure in Multiple Myeloma
Recently, The ASCO Post published an article titled "Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar, MD." On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to “cure” patients, in light of the fact that multiple myeloma has been...
Surbhi Sidana, MD, Comments on CAR T-Cell Therapy and Bispecific Antibodies Targeting Myeloma
The session’s invited discussant Surbhi Sidana, MD, Assistant Professor of Medicine, Stanford University, said CAR T-cell therapy and bispecific antibodies targeting myeloma are emerging as potentially effective options for patients with highly refractory disease. For this population of triple...
Bispecific Antibodies Advance in Relapsed or Refractory Multiple Myeloma
For the challenging population of patients with multiple myeloma who have become refractory to essentially all current treatments, new approaches are much needed. Early clinical trials data suggest bispecific antibodies may help meet this need, as suggested by studies presented at the 2021 ASCO...
FDA Alert: Clinical Trial Results Show an Increased Risk of Death Associated With Melphalan Flufenamide
The U.S. Food and Drug Administration (FDA) is alerting patients and health-care professionals that a clinical trial (OCEAN, Study OP-103; ClinicalTrials.gov identifier: NCT03151811) evaluating melphalan flufenamide with dexamethasone to treat patients with multiple myeloma showed an increased risk ...
Expert Point of View: Philip McCarthy, MD
Commenting on the updated results of the MAIA trial1 for The ASCO Post was Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York. Dr. McCarthy described how the...
MAIA Update: Overall Survival Benefit Reported With Daratumumab Plus Lenalidomide in Myeloma
In an updated analysis of the phase III MAIA trial, the addition of the monoclonal antibody daratumumab to the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone (D-Rd) significantly improved overall survival over lenalidomide/dexamethasone alone in patients newly diagnosed...
Paul G. Richardson, MD, on Multiple Myeloma and COVID-19: An Update
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses challenges patients with multiple myeloma have faced as a result of the COVID-19 pandemic and the research he and his international colleagues are conducting to better understand these difficulties and improve patient care.
FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Pretreated Patients With Multiple Myeloma
On July 9, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a...
Defining Cure in Multiple Myeloma
The past 2 decades have seen so many advances in the treatment of multiple myeloma; in addition, median patient survival has grown from just 3 years in the late 1990s to between 8 and 10 years today,1 with some patients exceeding that prognosis by many years. Although still considered a stubbornly...
Novel Targeted Agents for the Treatment of Myelofibrosis
“Progress lies not in enhancing what is, but in advancing toward what will be.” –Kahlil Gibran To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting &...
Novel BCL2 Inhibitor Shows Activity in CLL in Phase I Trial
The novel, selective BCL2 inhibitor lisaftoclax (APG-2575) has shown activity in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in a phase I study reported at the 2021 ASCO Annual Meeting.1 Preliminary data suggest that lisaftoclax stands out for its favorable safety...
Predicting Global Cancer Trends in 2021
Although we are just halfway through 2021, the outlook for improvements in global cancer trends looks grim. According to new estimates by the International Agency for Research on Cancer’s Global Cancer Observatory, the global cancer burden rose to 19.3 million cases and 10 million deaths in 2020...
Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
On May 20, 2021, nivolumab was approved for adjuvant treatment of patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.1,2 Supporting Efficacy Data Approval was based on findings from the...
